Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
Tóm tắt
Từ khóa
Tài liệu tham khảo
Ferlay, 2015, Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012, Int J Cancer, 136, E359, 10.1002/ijc.29210
El-Serag, 2007, Hepatocellular carcinoma: epidemiology and molecular carcinogenesis, Gastroenterology, 132, 2557, 10.1053/j.gastro.2007.04.061
Llovet, 2008, Sorafenib in advanced hepatocellular carcinoma, N Engl J Med, 359, 378, 10.1056/NEJMoa0708857
Cheng, 2009, Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial, Lancet Oncol, 10, 25, 10.1016/S1470-2045(08)70285-7
Cheng, 2013, Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial, J Clin Oncol, 31, 4067, 10.1200/JCO.2012.45.8372
Johnson, 2013, Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study, J Clin Oncol, 31, 3517, 10.1200/JCO.2012.48.4410
Cainap, 2015, Linifanib versus sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial, J Clin Oncol, 33, 172, 10.1200/JCO.2013.54.3298
Zhu, 2015, SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma, J Clin Oncol, 33, 559, 10.1200/JCO.2013.53.7746
Bruix, 2017, Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet, 389, 55, 10.1016/S0140-6736(16)32453-9
2017
Matsui, 2008, E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition, Int J Cancer, 122, 664, 10.1002/ijc.23131
Matsui, 2008, Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase, Clin Cancer Res, 14, 5459, 10.1158/1078-0432.CCR-07-5270
Tohyama, 2014, Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models, J Thyroid Res, 2014, 638747, 10.1155/2014/638747
Yamamoto, 2014, Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage, Vasc Cell, 6, 18, 10.1186/2045-824X-6-18
Schlumberger, 2015, Lenvatinib versus placebo in radioiodine-refractory thyroid cancer, N Engl J Med, 372, 621, 10.1056/NEJMoa1406470
Motzer, 2015, Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial, Lancet Oncol, 16, 1473, 10.1016/S1470-2045(15)00290-9
Ikeda, 2017, Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma, J Gastroenterol, 52, 512, 10.1007/s00535-016-1263-4
Tamai, 2017, Dose finding of lenvatinib in subjects with advanced hepatocellular carcinoma based on population pharmacokinetic and exposure-response analyses, J Clin Pharmacol, 57, 1138, 10.1002/jcph.917
Lencioni, 2010, Modified RECIST (mRECIST) assessment for hepatocellular carcinoma, Semin Liver Dis, 30, 52, 10.1055/s-0030-1247132
Bruix, 2011, Management of hepatocellular carcinoma: an update, Hepatology, 53, 1020, 10.1002/hep.24199
Eisenhauer, 2009, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur J Cancer, 45, 228, 10.1016/j.ejca.2008.10.026
Cocks, 2011, Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30, J Clin Oncol, 29, 89, 10.1200/JCO.2010.28.0107
Giesinger, 2016, Replication and validation of higher order models demonstrated that a summary score for the EORTC QLQ-C30 is robust, J Clin Epidemiol, 69, 79, 10.1016/j.jclinepi.2015.08.007
Terashima, 2014, Feasibility and efficacy of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma after sorafenib, Hepatol Res, 44, 1179, 10.1111/hepr.12266
Shao, 2013, A pilot study of hepatic arterial infusion of chemotherapy for patients with advanced hepatocellular carcinoma who have failed anti-angiogenic therapy, Liver Int, 33, 1413, 10.1111/liv.12207
Kudo, 2014, JSH consensus-based clinical practice guidelines for the management of hepatocellular carcinoma: 2014 update by the Liver Cancer Study Group of Japan, Liver Cancer, 3, 458, 10.1159/000343875
Boss, 2012, A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours, Br J Cancer, 106, 1598, 10.1038/bjc.2012.154
Ikeda, 2016, Safety and pharmacokinetics of lenvatinib in patients with advanced hepatocellular carcinoma, Clin Cancer Res, 22, 1385, 10.1158/1078-0432.CCR-15-1354
Lencioni, 2017, Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC, J Hepatol, 66, 1166, 10.1016/j.jhep.2017.01.012